Sort
48,018 grants matching “immunotherapy”
Promotion of tumor invasion and pseudosenescence by the aging microenvironment
$394,250Ashani T Weeraratna · Wistar Institute · R01 · FY2017 · CA
Machine Learning for Integrative Modeling of the Immune System in Clinical Settings
$394,250Nima Aghaeepour · Stanford University · R35 · FY2022 · GM
Cell Therapy Core: GMP/Vector Labs
$394,246Indreshpal Kaur · University Of Tx Md Anderson Can Ctr · P01 · FY2019 · CA
Inflammation and immunity in the crucible of premalignancy
$394,185Adrian Erlebacher · New York University School Of Medicine · R01 · FY2014 · CA
Lymphocyte and inflammatory cytokine markers of response in the first-in-human combination of anti-PD-1 mAb and IL-15/IL-15Ra complexes and investigation of mediators of anti-tumor immune responses
$394,181Mark P Rubinstein · Medical University Of South Carolina · R01 · FY2019 · CA
Increasing Thiols for Improving T cell Immunotherapy
$394,167Shikhar Mehrotra · Lipo-Immuno Tech, Llc · R41 · FY2022 · CA
Molecular Mechanisms of Immune Tolerance
$394,085Roberta Pelanda · National Jewish Health · T32 · FY2023 · AI
Investigating the prognostic role of intrinsic immune evasion mechanisms in HNSCC
$394,071Xuefeng Wang · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · DE
Targeting of STAT3 Signaling Enhances Efficacy of Breast Cancer Immunotherapy
$394,043Ralph A. Reisfeld · Scripps Research Institute, The · R01 · FY2010 · CA
Targeting of STAT3 Signaling Enhances Efficacy of Breast Cancer Immunotherapy
$394,043Ralph A. Reisfeld · Scripps Research Institute, The · R01 · FY2009 · CA
Function of IL35+ B cells in pancreatic cancer
$394,032Yuliya Pylayeva-Gupta · Univ Of North Carolina Chapel Hill · R37 · FY2023 · CA
CLINICAL TRIALS OF ALLOGENEIC STEM CELL TRANSPLANT IN LYMPHOHEMATOPOIETIC DISORDE
$394,006Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2007 · CA
Fatty acid metabolism regulates ferroptosis in mutant KRAS lung cancer
$393,994Pier P Scaglioni · University Of Cincinnati · R01 · FY2023 · CA
P-3: Preclinical and Clinical Studies of MUC1 Glycopeptide Vaccine Strategies in
$393,936Sandra Jane Gendler · Mayo Clinic Rochester · P50 · FY2007 · CA
Advanced Rigidity-based Material for Enhanced Immunotherapy
$393,896Lance C Kam · Columbia University Health Sciences · R01 · FY2018 · AI
The integrated stress response and the microenvironment in melanoma progression
$393,894Constantinos Koumenis · University Of Pennsylvania · R01 · FY2024 · CA
Fruit exosome-like particles for therapeutic delivery of extracellular miRNAs
$393,877Huang-Ge Zhang · University Of Louisville · UH2 · FY2014 · TR
Eradication of Escaped Variant Tumor Cells for Cancer Immunotherapy
$393,863Yong Lu · Methodist Hospital Research Institute · R01 · FY2022 · CA
FUNCTIONAL ANTIHIV-1 GP41 HUMAN MONOCLONAL ANTIBODIES
$393,858University Of South Florida · R01 · FY2001 · HL
FUNCTIONAL ANTIHIV-1 GP41 HUMAN MONOCLONAL ANTIBODIES
$393,858University Of South Florida · R01 · FY2000 · HL
Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies
$393,853Constantine S. Mitsiades · Dana-Farber Cancer Inst · R01 · FY2025 · CA
Human studies of Listeria monocytogenes vectors
$393,810Massachusetts General Hospital · R01 · FY2004 · AI
Human studies of Listeria monocytogenes vectors
$393,810Massachusetts General Hospital · R01 · FY2003 · AI
Human studies of Listeria monocytogenes vectors
$393,810Massachusetts General Hospital · R01 · FY2002 · AI
Understanding the Behavior of Novel IL13Ralpha2-directed T cell Engager for GBM
$393,773Irina V Balyasnikova · Northwestern University At Chicago · R01 · FY2023 · NS